**Name of Journal:** *World Journal of Psychiatry*

**Manuscript NO:** 65099

**Manuscript Type:** MINIREVIEWS

**Is there a place for cellular therapy in depression?**

do Prado-Lima PAS *et al*. Stem cells and depression

Pedro Antônio Schmidt do Prado-Lima, Zaquer Suzana Munhoz Costa-Ferro, Bruno Solano de Freitas Souza, Ivana Beatrice Manica da Cruz

**Pedro Antônio Schmidt do Prado-Lima, Zaquer Suzana Munhoz Costa-Ferro,** Brain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul, Porto Alegre 90610-000, Rio Grande do Sul, Brazil

**Zaquer Suzana Munhoz Costa-Ferro, Bruno Solano de Freitas Souza,** Center for Biotechnology and Cell Therapy, São Rafael Hospital, Salvador 41253-190, Bahia, Brazil

**Zaquer Suzana Munhoz Costa-Ferro, Bruno Solano de Freitas Souza,** D’Or Institute for Research and Education (IDOR), Salvador 41253-190, Bahia, Brazil

**Bruno Solano de Freitas Souza,** Laboratory of Tissue Engineering and Immunopharmacology, Gonçalo Moniz Institute, Fiocruz, Salvador 40296-710, Bahia, Brazil

**Ivana Beatrice Manica da Cruz,** Health Sciences Center, Federal University of Santa Maria, Santa Maria 97105900, RS, Brazil

**Author contributions:** do Prado-Lima PAS was responsible for the overall organization of the manuscript structure and writing and reviewing the epidemiological part of depression and the inflammatory role in this psychiatric disorder for the survey and comments related to clinical trials involving stem cell depression that are in progress; Costa-Ferro ZSM and Souza BSDF were responsible for compiling, organizing, and description of the tables related to the main studies involving stem cells in depression and other associated diseases; da Cruz IBM was also responsible for reviewing the neuroinflammatory aspects related to depression, the general organization of the figure, formatting, and submission of the manuscript; all authors contributed to the general writing, revising the text, and scientific quality of the manuscript.

**Supported by** Conselho Nacional de Desenvolvimento Cientifico -CNPq.

**Corresponding author: Pedro Antônio Schmidt do Prado-Lima, PhD, Academic Research,** Brain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul, Avenida Ipiranga 6690, Porto Alegre 90610-000, Rio Grande do Sul, Brazil. paspl@uol.com.br

**Received:** February 28, 2021

**Revised:** May 5, 2021

**Accepted:** August 13, 2021

**Published online:**

**Abstract**

Although efforts have been made to improve the pharmacological treatment of depression, approximately one-third of patients with depression do not respond to conventional therapy using antidepressants. Other potential non-pharmacological therapies have been studied in the last years, including the use of mesenchymal stem cell therapies to treat depression. These therapies are reviewed here since it is clinically relevant to develop innovative therapeutics to treat psychiatric patients. Experimental data corroborate that mesenchymal stem cell therapy could be considered a potential treatment for depression based on its anti-inflammatory and neurotrophic properties. However, some clinical trials involving treatment of depression with stem cells are in progress, but with no published results. These studies and other future clinical investigations will be crucial to define how much mesenchymal stem cells can effectively be used in psychiatric clinics as a strategy for supporting depression treatment.

**Key Words:** Mood disorders; Stem cells transplant; Mesenchymal stem-cells transplant; Inflammation; Immunomodulation; Depression

do Prado-Lima PAS, Costa-Ferro ZSM, Souza BSF, da Cruz IBM. Is there a place for cellular therapy in depression? *World J Psychiatr* 2021; In press

**Core Tip:** In this study, the authors performed a narrative review regarding the role of inflammation in depression and investigated the evidence suggesting that the use of stem cell therapies could be a realistic, safe, and effective strategy for treating depression.

**INTRODUCTION**

Depression is a highly prevalent disorder that affects the entire life span. In adults, the 12-mo prevalence of the major depressive disorder is approximately 6%[1], and the lifetime risk is 15%-18%[2]. It is one of the leading causes of disability worldwide[3]. In clinical terms, depression is a complex disorder with devastating consequences for patients and their families, provoking psychological suffering due to sadness, anxiety, anguish, and guilt; diminished cognitive performance; and impaired attention, memory, and reasoning. Moreover, depression has negative influences on decision-making and interpretation of facts, leading to wrong decisions. Depression is also a risk factor for the development and outcome of many chronic non-transmissible diseases, such as cardiovascular diseases and diabetes[4-6]. Evidence also suggests a small and positive association between depression and the overall risk of cancer, including liver and lung cancer[7].

Pharmacological treatment for depression has been available since 1957, when imipramine, a tricyclic antidepressant, and iproniazid, a monoamine oxidase inhibitor, were released[8,9]. In more than six decades, many drugs have been released commercially, improving the tolerability and safety of antidepressant treatment. However, with few exceptions, these medications' intended mechanism was to increase serotonin, noradrenaline, and dopamine availability. Although efforts have been made to improve pharmacological treatment of depression, approximately one-third of patients fail to respond to conventional antidepressants[10]. This limitation in the anti-depressive efficiency is possibly related to the mechanism of action of the available antidepressants. Therefore, it is clinically relevant to develop innovative therapeutic strategies based on the pathophysiological aspects of depression.

Several lines of evidence suggest that chronic inflammatory states may be related to depression etiopathogenesis in recent years. This evidence made way for researchers to develop new anti-inflammatory therapies that could alleviate symptoms and the progression of depression[11,12]. In a previous study, our group investigated the possible use of stem cell therapy. Our hypothesis was based on the anti-inflammatory and neurodegenerative properties of stem cells, which could treat the pathogenic state that maintains depression.

Here, we performed a narrative review regarding the role of inflammation in depression and investigated the evidence suggesting that the use of stem cell therapies could be a realistic, safe, and effective strategy for treating depression.

**Inflammation provoking depression**

A colossal research effort has been made in the last 60 years to unravel and understand the neurobiological processes underlying depression. This process started since tricyclic and monoamine-oxidase effectiveness in depression treatment was proven in 1957[13], and pharmacological drugs have been introduced in clinical practice. The attempt to identify the neurobiological processes and causes of depression started with understanding the antidepressant mechanisms of action. This strategy led to the identification of monoamines and their role in depression. Further, the development of almost all antidepressant medications was based on these discoveries.

In 1968, Carrol *et al*[14] postulated the role of the hypothalamus-hypophysis-adrenal axis (HPA axis) in depression etiopathogenesis, subsidizing the HPA axis hypothesis. The role of glucocorticoid hippocampal receptors in HPA-axis modulation in depression has been extensively studied. Chronic stress modulates the inflammatory process that plays a crucial role in the neurobiological aspects underlying depression[15]. However, this research strategy has not led to the development of antidepressant medications.

The interest in the role of immunological and inflammatory mechanisms in depression is a natural consequence of HPA axis studies since cortisol can modulate these responses. Furthermore, consistent data on the role of psychological stress on depression development involves alterations in immune functions, mainly due to chronic inflammatory states[16,17].

The link between emotional stress, depression, and inflammation seems to involve evolutionary issues. Several lines of evidence suggest that metabolic, endocrine, and immune responses co-evolved, helping animal surveillance since animals need to actively seek food by exposing themselves to injury or predation and also need to defend themselves from pathogens[18].

In addition to triggering a fight or flight response, stress is characterized by increases in heart rate, blood pressure, cortisol, and catecholamines. It also activates inflammatory pathways in peripheral blood mononuclear cells[9]. However, when stress exposure occurs continuously without being resolved, metabolic and physiological responses are triggered that contribute to the formation of chronic inflammatory states[19]. Figure 1 shows the association between stress and neuroinflammation in depression etiopathogenesis based on several previous reviews[14,18,20].

**How chronic stress, through inflammation, can trigger depression?**

Although acute stress induces an immunosuppressed state, chronic stress exposure has an antagonistic pro-inflammatory effect. As a result, the anti-inflammatory state develops to a chronic inflammatory condition due to the factors produced by exposure to chronic stress, such as catecholamines[19].

Catecholamines released by psychological stress can promote damage-associated molecular patterns (DAMPs), including high mobility group box 1 (HMGB1), ATP, and heat shock proteins. DAMPs are inflammatory signaling proteins released by different stress levels, including psychological factors[21,22]. For example, HMGB1 is a nuclear protein that is present in all cell types.

Once released, it activates through TLR4 and RAGE receptor inflammatory cascades, including the pyrin domain-containing protein 3 (NLRP3) inflammasome[20,23]. Inflammasomes are cytosolic protein complexes formed in myeloid cells, such as monocytes, in response to pathogenic microorganisms or sterile stressors, such as psychological stress. Activation of the NLRP3 inflammasome subsequently leads to caspase-1 activation, which in turn provokes cleavage of the pro-inflammatory cytokines interleukine-1β (IL-1β) and IL-18[20], and nuclear factor-κB (NF-κB) pathway activation with subsequent IL-6 release[21].

All events occurring outside the brain must change the brain physiology to trigger depression. There are three mechanisms by which inflammation in peripheral tissues reaches the brain, overcoming the blood-brain barrier (BBB). In the humoral pathway, pro-inflammatory cytokines, such as IL-1β, IL-18, IL-6, and TNFa, enter the brain through the leaky region of the BBB, such as circumventricular organs, or the binding of these cytokines to saturable transport molecules in the BBB[9]. In the neural pathway, the same cytokines bind peripheral afferent nerve fibers, such as the vagus nerve, which stimulates catecholaminergic fibers in the brain and translates into central cytokine signals. Moreover, activated immune cells, such as monocytes, reach the brain vasculature and parenchyma through trafficking mechanisms[9]. These different mechanisms act in coordination to trigger inflammation in the brain. For example, peripheral TNFa can stimulate microglia to produce CC-chemokine ligand 2 (CCL2), a chemokine that attracts monocytes to the brain[24]. Cytokines such as IL-1β and TNFa can also stimulate astrocytes to produce chemokines such as CCL2 or CXC chemokine ligand 1, thus attracting immune cells to the brain[25].

Peripheral inflammatory molecules induce astrocytes and microglia activation into the brain, triggering a complex inflammatory cascade. This cascade interferes with neurotransmission, the HPA axis, and neurotrophin balance synapses. An example of the peripheral effects on neuroinflammation is the expression of IL-1β and TNFa. These cytokines can induce the overexpression of some molecules, such as p38 mitogen-activated protein kinase, which alters the serotonin transporter, leading to a decrease in the availability of serotonin in the synaptic cleft[9].

IL-6, another pro-inflammatory cytokine, contributes to the generation of high levels of reactive oxygen and nitrogen species, which cause oxidative stress. This reaction decreases tetrahydrobiopterin (BH4) availability, a cofactor enzyme in monoamine synthesis, diminishing serotonin, noradrenaline, and dopamine availability. The cytokines, particularly IL-1β and TNFa molecules, alter the kynurenine pathway by increasing quinolinic acid levels (QA). The elevation of QA levels occurs by the activity of the indoleamine 2,3-dioxygenase enzyme, which catalyzes tryptophan into kynurenine. As QA synthesis involves tryptophan, depletion of this amino acid directly affects serotonin production. Furthermore, QA has a dangerous effect on the brain by increasing oxidative stress, astrocyte degeneration, and neuronal apoptosis. Therefore, inflammatory activation generates metabolic alterations that can contribute to the risk of depression and suicide[9,16,26-28].

QA and cytokines also have a critical synergistic effect on glutamate metabolism. QA directly stimulates N-methyl-D-aspartate receptors (NMDA), decreasing glutamate re-uptake and stimulating glutamate release by astrocytes[9]. In astrocytes, pro-inflammatory cytokines decrease the expression of glutamate re-uptake pumps, increasing glutamate release. This combined action triggers high glutamate levels inside and outside the synapses, allowing the activation of extra-synaptic NMDA receptors. Alterations in the glutamatergic pathway induce a decrease in molecules with neurogenic functions, particularly brain-derived neurotrophic factor (BDNF)[9,29,30]. It should be noted that conventional antidepressant medication acts by increasing monoamine availability in the synapse, thereby increasing BDNF and consequently promoting neurogenesis through BDNF action on its receptor TrkB[31,32].

The effect of neuroinflammation has an impact on neurocircuit function. Inflammation has been associated with a decrease in responsiveness to reward stimuli, particularly in the ventral striatum. For example, in healthy volunteers, the administration of low doses of endotoxin, which can increase pro-inflammatory cytokine levels more safely, is associated with the development of depressive mood. This effect was related to the diminished activity of the ventral striatum to the anticipated reward measured by functional magnetic resonance imaging (fMRI)[33]. Interferon-a administration to treat chronic hepatitis virus C infection-induced depression, anhedonia, and fatigue. This administration reduced ventral striatum activation with reward-anticipatory stimuli during fMRI. In the same study, positron emission tomography demonstrated an association between the behavior and fMRI results with 18F-dopa turnover in the ventral striatum; changing presynaptic dopamine function was consistent with decreased dopamine synthesis or release[34]. Evidence also described that typhoid immunization could produce inflammation by IL-6 augmentation and activation of the subgenual anterior cingulate cortex (sgACC), a region implicated in depression and depressive symptoms. Moreover, the elevation in IL-6 concentrations decreases the connectivity between the sgACC and amygdala, medial prefrontal cortex, superior temporal sulcus, and ventral striatum[35].

Many of these brain changes induced by peripheral inflammation and neuroinflammation have been described in experimental and epidemiological studies that involve chronic exposure to social stress. Exposure to social stress can increase soluble TNFa receptors and IL-6 molecules. The elevation of soluble TNFa receptor can increase the dorsal ACC and anterior insula activity, two brain regions that process rejection-related distress and negative affect[36,37]. Experimental protocols where stress was induced in the laboratory conditions described the increased feelings of social and rejection behaviors associated with inflammatory activation by increasing IL-6 Levels and high left amygdala activity, a brain area directly related to detection and response threats[38].

Child abuse is one of the main risk factors for chronic stress and inflammation in the etiopathogenesis of depression. Early adversity is considered a risk factor for developing depression, and emotional abuse shows the strongest association, followed by neglect[39]. A growing body of literature showed that early adversity could shape immune cells and inflammatory cascades. A meta-analysis performed by Baumeister *et al*[40] showed that adult individuals exposed to childhood trauma had elevated baseline blood levels of C-reactive protein, IL-6, and TNFa.

Therefore, the pieces of evidence commented here can support the hypothesis that depression is an inflammatory disease. Here supports the hypothesis that depression is an inflammatory disease. A meta-analysis showed higher peripheral levels of IL-6, TNFa, IL-10, IL-12, IL-13, IL-18, CCL2, IL-1b receptor antagonist, soluble IL-2 receptor, and soluble TNF receptor 2 in depressive patients. In comparison, the INFγ blood levels were lower in these individuals. Moreover, the concentrations of IL-1b, IL-2, IL-4, IL-8, IL-5, CCL3, IL-17, the soluble IL-6 receptor, and the transforming growth factor-beta one did not present differences associated with depression[41].

**Antidepressants and anti-inflammatory drugs on depression**

As inflammation could trigger depression, the logical question is that anti-inflammatory drugs could positively affect depression. A recent meta-analysis on this issue included studies involving the impact of anti-depressive drugs on different pro and anti-inflammatory cytokines (IL-1b, IL-2, IL-4, IL5, IL-6, IL-8, IL-10, IL-12, TNFa, INFy, and others)[42]. Moreover, the meta-analysis found that antidepressant responders had lower levels of IL-8 than non-responders. Antidepressant treatment only decreased TNFa levels, IL-5, and granulocyte-macrophage colony-stimulating factor in responsive patients. However, when treatment-resistant patients were compared to non-depressed controls, IL-6, IL-8, TNFa, C-reactive protein (CRP), and macrophage inflammatory protein-1 were associated with poor treatment outcomes[43].

Furthermore, it has been tested for its potential anti-inflammatory use in the attenuation of depressive symptoms. A meta-analysis of randomized controlled trials showed an antidepressant effect of anti-cytokine drugs[44]. The anti-TNFa adalimumab and etanercept, except infliximab, showed an antidepressant effect. Previous studies have also described some antidepressant effects of dupilumab, an antagonist drug of the alpha subunit of the IL-4 receptor, and ustekinumab, which inactivates IL-12 and IL-23 cytokines[45]. Randomized controlled clinical trials have described the anti-depressive effect of some anti-inflammatory drugs such as (1) glycyrrhizic acid, an HMGB1 inhibitor, was useful as an add-on with selective serotonin re-uptake inhibitor in the treatment[45]; (2) minocycline, a tetracycline antibiotic, that lowers neuroinflammation by inhibiting microglial activation and inhibiting the release of HMGB1[46]. However, minocycline was effective only in patients with baseline levels of CRP > 2.8 mg/L[47]; and (3) although bipolar disorder (BD) is not in the scope of this review, a clinical trial stands out here describing that coadministration of N-acetylcysteine and aspirin for 16 wk was associated with a reduction in depressive symptoms in BD-patients[48].

Despite the evidence suggesting that anti-inflammatory drugs could help treat depression, further investigations are needed to evaluate the safety of prolonged periods of anti-inflammatory co-treatments in patients with depression[49]. In this context, the search for non-pharmacological anti-inflammatory therapeutic strategies is of great interest to the psychiatric clinic, as in the case of stem cell treatments, which have been applied in other clinical areas, has been intensively investigated for more than 10 years[50,51].

**Clinical use of adult stem cells**

Stem cells, bone marrow mononuclear stem cells (BMMCs) and mesenchymal stem cells (MSCs), are defined as adult unspecialized cells with self-renewal ability and high regenerative potential[52,53]. Adult stem cells can differentiate into several cell lines and activate or inhibit a sequence of molecules involved in anti-inflammatory and anti-apoptotic pathways[52,53]. MSCs were first detected in the bone marrow. However, they can also be isolated from the umbilical cord tissue and adipose tissue, among other sources[52-57].

Human stem cells were first described in the middle of the 20th century in mouse models[58,59], and their transplantation was first applied in humans in 1957[60,61]. In the following decades, bone marrow stem cells-transplants have saved the lives of patients suffering from a great variety of diseases, mainly conditions affecting the hematopoietic or immunological system. Due to relatively low MSc-immunogenicity, the transplantation of these cells presents a low risk of tumorigenicity and less complicated ethical/regulatory issues compared to embryonic pluripotent stem cells[57,62].

Studies of therapeutic MSCs applications have expanded, showing that both allogeneic and autologous transplantation is possible due to the low immunogenicity of these cells and immunomodulatory effects[63]. These studies, including experimental investigations performed in several animal models of inflammatory and autoimmune-mediated disorders, such as systemic lupus erythematosus, rheumatoid arthritis, and myasthenia gravis[64-66] and other conditions associated with inflammatory disturbances such as sepsis[67], lung fibrosis[68], diabetes[69], atherosclerosis[70], and osteoarthritis[71].

**Stem cells-based therapies for neuroinflammatory disorders**

Stem cell therapies have effectively emerged as a standard for the treatment of both subacute and chronic inflammatory processes and neurological disorders. Investigations have suggested the potential use of adult stem cells therapy to treat several neurological conditions, such as multiple sclerosis[72], autoimmune encephalomyelitis[73], Alzheimer's disease, and other dementia conditions[74], Parkinson's disease[75], and epilepsy[76]. Most studies emphasize the immunomodulatory nature of adult stem cells, with its therapeutic efficiency related to neurological diseases, particularly triggering anti-inflammatory states.

For example, in epilepsy, seizure activity can induce pro-inflammatory molecules, therefore affecting the severity and frequency of seizures[77]. Transplantation of BMMCs or human umbilical cord blood mononuclear cells in experimental epilepsy models induced significant improvements in neurological function[78,79]. After a seizure, brain injury induces a highly regulated cascade of biological events, characterized by the release of cytokines, chemokines, and protectins in the neuronal microenvironment[80,81], which was attenuated by adult stem cell transplantation, decreased the inflammatory states, and promoted tissue repair through cell-cell interactions and paracrine effects[80-83]. Furthermore, some evidence showed that adult stem cells stimulate angiogenesis and endothelial repair through paracrine actions[82,83]. In Alzheimer's disease, MSCs have been shown to reduce IL-1, IL-2, TNFa, and IFN-γ in the serum and oxidative stress, which showed an anti-inflammatory effect[84].

Among the most relevant stem cells' action mechanisms is the release of extracellular vesicles carrying soluble factors, microRNAs, and organelles[85]. Initially, the release of extracellular vesicles was thought to represent a disposal mechanism by which cells eliminate unwanted proteins and other molecules. Among the extracellular vesicle subtypes, significant attention has been given to exosomes. Exosomes are small membrane vesicles with a diameter between 40 and 100 nm[86], and different biological molecules, including proteins, lipids, and nucleic acids that may be captured and act in a biologically active manner on recipient cells. Various studies have described the beneficial actions of MSCs by delivering exosomes instead of cells[87,88]. Therefore, MSC cells or exosome transplantation could offer an efficient and safe non-pharmacological therapy to treat neurological conditions.

**Potential use of BMMCs and MSCs in depression: evidence from preclinical studies in experimental models**

The optimistic results obtained from experimental studies involving BMMCs and MSCs in the therapy of neurological conditions open the perspective of developing non-pharmacological cell treatments for psychiatric disorders. The main results of these studies are presented in Table 1. The potential therapeutic effects of adult cells-based therapies have been well characterized across *in vivo* studies of depression models, including an investigation performed by our research team[89]. This study evaluated the effect of BMMC transplantation on the restoration of sucrose preference in rats subjected to chronic stress. This well-established model triggers depressive symptoms in animals. The study also evaluated the potential inflammatory modulation of BMMCs in stressed rats. The levels of pro-and anti-inflammatory cytokines in different brain areas, blood, and spleen were also quantified. In this protocol, escitalopram was used as a positive antidepressant control. The results demonstrated that BMMCs transplantation in stressed rats: (1) Restored spontaneous sucrose consumption in stressed rats; (2) Had a robust anti-inflammatory effect, increasing the levels of the anti-inflammatory cytokine IL-10 in the amygdala, hippocampus, frontal cortex, other brain areas, and in the spleen and blood; a lowering effect on pro-inflammatory cytokine levels (IL-1 β, IL-6, TNFa, and INF-γ) was also detected in the same brain and peripheral tissues; and (3) Decreased levels of oxidized DNA quantified by 8'2-deoxyguanosine. In summary, the therapeutic use of BMMCs presented a positive impact on symptoms of depressed rats, and possible mechanisms involved in this effect include immunomodulation of inflammatory states in both the peripheral and central nervous systems.

Another recent study performed by an independent research team verified the results of do Prado-Lima *et al*[89] involving potential therapeutic MSC-transplantation in depression by anti-inflammatory action. The experimental protocol used adipose-derived mesenchymal stem cells (ADSCs) injected into C57BL/6 mice on the 21st day of a protocol of 42 d of chronic mild stress (CMS). The animals were tested by three behavioral assays: sucrose preference, tail suspension, and forced swimming test. All tests are broadly recognized as behavioral assays to identify depressive and anti-depressive chemical and behavioral factors. ADSC transplantation remedied depressive-like behaviors. The authors also observed that ADSC treatment reversed and prevented the increase in the production of some pro-inflammatory cytokines (CCL2, TNFa, IL-1β, and IL-6) in the serum and promoted the expression of BDNF and its receptor TrkB in the brain tissue. ADSC treatment increased the nuclear factor-E2 related factor 2 (Nrf2), which in turn has an anti-inflammatory effect by inhibiting TLR4/NF-κB pathway activation. Immunofluorescence detection revealed that the number of ionized calcium-binding adaptor molecule 1 (Iba1+), a protein expressed only in microglia and involved in its activation, decreased after ADSC treatment. In the same study, Nrf2-modified ADSCs were co-cultured with microglia cells and then exposed to lipopolysaccharide (LPS). Nrf2 downregulation decreased the protective effects of ADSCs against LPS-induced microglial activation and M1 polarization; however, Nrf2 overexpression markedly suppressed LPS-induced TLR4/NF-κB expression in microglial cells[90].

Kin *et al*[91] implanted the encapsulated MSCs (eMSCs) into the lateral ventricle and observed antidepressant effects *via* neurogenic pathways in Wistar Kyoto rats. These rats exhibited congenitally higher depression-like behaviors and resistance to conventional antidepressant treatments. Therefore, Kyoto rats are considered a promising model for treatment-resistant depression. The implantation of eMSCs counteracted depressive-like behavior on days 13 to 15 after implantation and enhanced endogenous neurogenesis in the subventricular zone and the dentate gyrus of the hippocampus. The eMSCs displayed a robust and stable secretion of vascular endothelial growth factor, BDNF, fibroblast growth factor 2, and ciliary neurotrophic factor. Implantation of eMSCs into the lateral ventricle activated relevant pathways associated with these growth factors.

Li *et al*[92] described the therapeutic action of human umbilical cord MSCs (hUC-MSCs) on chronic middle stress in mice. The animals were induced with hUC-MSCs once a week for four weeks for 42 d. The hUC-MSC treatment induced downregulation of some pro-inflammatory genes (GFAP, Iba1, Il-1, TNF, IL-1b, and TNFa). Moreover, the treatment also downregulated IL-10, transforming growth factor-β and AMPA gene expression. The authors reported a modulation in the microglia M1/M2 polarization balance and a decrease in neuroinflammation involving complement C3 molecules, specifically in the C3a-C3aR pathway.

Therapy efficacy using BMMCs-derived exosomes in rats with depression induced by corticosterone treatment was performed by Guo *et al*[93]. The exosome therapy upregulated miR-26a microRNA, increased hippocampal tissue proliferation, and suppressed apoptosis in depressive-like rats. Treatment decreased oxidative stress and inflammation by inducing high superoxide dismutase antioxidant enzyme levels and decreasing lipoperoxidation, TNFa, and IL-1β levels in both serum and hippocampus.

Another study administered natural killer (NK)-cell-derived exosomes carrying miR-207, capable of inhibiting the NF-κB signaling pathway in astrocytes. This exosome treatment was effective in diminishing depressive symptoms in mice submitted to CMS and decreased the levels of IL-1b, IL-6, and TNFa released by astrocytes. The critical element of the exosome effect was the presence of the miR-207 molecule. When NK-cells were transfected with miR-207 inhibitor and exosomes were produced by and injected in astrocytes, the impact on IL-1b, IL-6, and TNFa levels was no longer observed[94].

**Clinical trials in depressive patients**

The results from different experimental studies strongly support the potential therapeutic use of stem cells in treating depression. However, while data from experimental models have shown beneficial effects in depression, gaps remain to be explored. Further studies are needed to clarify whether any MSc type could be as effective and safe as an antidepressant therapy. For example, MSCs from the bone marrow have the best potential to treat depression, considering the significant data regarding them. However, ethical problems are to be considered when it comes to autologous transplants that require surgical intervention to obtain these cells. Moreover, heterologous bone marrow cell transplantation could be an acceptable clinical strategy. However, further studies are needed to assess the safety of using these cells from donors with a different genetic background than the patient.

In addition, further studies are needed to establish the optimal dose, administration route, and fundamental mechanisms of action. The translation ability of such experimental models to the target human population, possibly composed of refractory and polypharmacy patients, merits further discussion. For instance, previous efforts with several compounds that passed through animal studies with promising results have failed in clinical trials, partially due to the poor validity of such models to represent the target patient population[95].

Due to these gaps, the first clinical trials involving cell-based products or exosomes to treat depression have been registered to international platforms. At Clintrial.gov, the keywords "depression," "depressive disorder," and "cell therapy" were used to perform the search. This research led us to find four registered clinical studies involving the use of MSCs as a treatment for patients with depression. Currently, four clinical studies (phases 1 and 2) are under evaluation for the safety, efficacy, and tolerability of the administration of MSCs and exosomes (Table 2). However, most of the results are not yet available, as these studies are still in the patient recruitment phase. Therefore, the results are anticipated to be published from these trials soon.

**CONCLUSION**

Cell therapy, through BMMC or MSC transplantation or the administration of cell products such as exosomes, may have a place in treatment-resistant depression. The number of preclinical studies is still limited; therefore, further development of clinical trials is encouraged.

As technology and knowledge involving all aspects of cells or cell-based products develop, the easier it is to identify the best alternative (cells or exosomes) to try as an antidepressant treatment, the lower the costs and the more established the routines. A significant development should be expected to understand its potential and possible side effects better.

Despite the limited number of preclinical studies, many issues have not been identified, such as how long the antidepressant effect persists. It is a critical question that has consequences for the feasibility of these procedures as treatment. Because of the challenge that represents the treatment of resistant depression, the possibility of an effective treatment in this chronic, severe, and prevalent condition must be explored.

For this, a more significant number of clinical studies are needed to evaluate several open questions considering the variability of the effectiveness of the use of stem cells in the treatment of depression.

**ACKNOWLEDGEMENTS**

The authors would like to thank Miss Ana Pereira do Prado Lima, who produced and allowed the publication of the graphic schemes used in Figure 1 of this review and allowed its use.

**REFERENCES**

1 **Kessler RC**, Bromet EJ. The epidemiology of depression across cultures. *Annu Rev Public Health* 2013; **34**: 119-138 [PMID: 23514317 DOI: 10.1146/annurev-publhealth-031912-114409]

2 **Bromet E**, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, de Graaf R, Demyttenaere K, Hu C, Iwata N, Karam AN, Kaur J, Kostyuchenko S, Lépine JP, Levinson D, Matschinger H, Mora ME, Browne MO, Posada-Villa J, Viana MC, Williams DR, Kessler RC. Cross-national epidemiology of DSM-IV major depressive episode. *BMC Med* 2011; **9**: 90 [PMID: 21791035 DOI: 10.1186/1741-7015-9-90]

3 **Global Burden of Disease Study 2013 Collaborators**. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015; **386**: 743-800 [PMID: 26063472 DOI: 10.1016/S0140-6736(15)60692-4]

4 **van Sloten T**, Schram M. Understanding depression in type 2 diabetes: a biological approach in observational studies. *F1000Res* 2018; **7** [PMID: 30135724 DOI: 10.12688/f1000research.13898.1]

5 **Bucciarelli V**, Caterino AL, Bianco F, Caputi CG, Salerni S, Sciomer S, Maffei S, Gallina S. Depression and cardiovascular disease: The deep blue sea of women's heart. *Trends Cardiovasc Med* 2020; **30**: 170-176 [PMID: 31109802 DOI: 10.1016/j.tcm.2019.05.001]

6 **Bădescu SV**, Tătaru C, Kobylinska L, Georgescu EL, Zahiu DM, Zăgrean AM, Zăgrean L. The association between Diabetes mellitus and Depression. *J Med Life* 2016; **9**: 120-125 [PMID: 27453739]

7 **Jia Y**, Li F, Liu YF, Zhao JP, Leng MM, Chen L. Depression and cancer risk: a systematic review and meta-analysis. *Public Health* 2017; **149**: 138-148 [PMID: 28641155 DOI: 10.1016/j.puhe.2017.04.026]

8 **Kuhn R**. [Treatment of depressive states with an iminodibenzyl derivative (G 22355)]. *Schweiz Med Wochenschr* 1957; **87**: 1135-1140 [PMID: 13467194]

9 **Bruel O**. [Treatment of depressive states with hematoporphyrin Nencki; a survey based on 320 personal ambulant cases]. *Psychiatr Neurol (Basel)* 1957; **133**: 1-17 [PMID: 13420229]

10 **Rush AJ**, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR\*D report. *Am J Psychiatry* 2006; **163**: 1905-1917 [PMID: 17074942 DOI: 10.1176/ajp.2006.163.11.1905]

11 **Miller AH**, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. *Nat Rev Immunol* 2016; **16**: 22-34 [PMID: 26711676 DOI: 10.1038/nri.2015.5]

12 **Beurel E**, Toups M, Nemeroff CB. The Bidirectional Relationship of Depression and Inflammation: Double Trouble. *Neuron* 2020; **107**: 234-256 [PMID: 32553197 DOI: 10.1016/j.neuron.2020.06.002]

13 **Thuillier J.** Then years that changed the face of mental illness. London: Martin Dunitz Ltd, 1999

14 **Carroll BJ**, Martin FI, Davies B. Pituitary-adrenal function in depression. *Lancet* 1968; **1**: 1373-1374 [PMID: 4172674 DOI: 10.1016/s0140-6736(68)92072-2]

15 **Juruena MF**, Bocharova M, Agustini B, Young AH. Atypical depression and non-atypical depression: Is HPA axis function a biomarker? A systematic review. *J Affect Disord* 2018; **233**: 45-67 [PMID: 29150144 DOI: 10.1016/j.jad.2017.09.052]

16 **Franklin TC**, Xu C, Duman RS. Depression and sterile inflammation: Essential role of danger associated molecular patterns. *Brain Behav Immun* 2018; **72**: 2-13 [PMID: 29102801 DOI: 10.1016/j.bbi.2017.10.025]

17 **Gałecki P**, Talarowska M. Inflammatory theory of depression. *Psychiatr Pol* 2018; **52**: 437-447 [PMID: 30218560 DOI: 10.12740/PP/76863]

18 **Fumagalli M**, Sironi M, Pozzoli U, Ferrer-Admetlla A, Pattini L, Nielsen R. Signatures of environmental genetic adaptation pinpoint pathogens as the main selective pressure through human evolution. *PLoS Genet* 2011; **7**: e1002355 [PMID: 22072984 DOI: 10.1371/journal.pgen.1002355]

19 **Rohleder N**. Stress and inflammation - The need to address the gap in the transition between acute and chronic stress effects. *Psychoneuroendocrinology* 2019; **105**: 164-171 [PMID: 30826163 DOI: 10.1016/j.psyneuen.2019.02.021]

20 **Leonard BE**. Inflammation and depression: a caUnited Statesl or coincidental link to the pathophysiology? *Acta Neuropsychiatr* 2018; **30**: 1-16 [PMID: 28112061 DOI: 10.1017/neu.2016.69]

21 **Fleshner M**. Stress-evoked sterile inflammation, danger associated molecular patterns (DAMPs), microbial associated molecular patterns (MAMPs) and the inflammasome. *Brain Behav Immun* 2013; **27**: 1-7 [PMID: 22964544 DOI: 10.1016/j.bbi.2012.08.012]

22 **Fleshner M**, Frank M, Maier SF. Danger Signals and Inflammasomes: Stress-Evoked Sterile Inflammation in Mood Disorders. *Neuropsychopharmacology* 2017; **42**: 36-45 [PMID: 27412959 DOI: 10.1038/npp.2016.125]

23 **Rana T**, Behl T, Mehta V, Uddin MS, Bungau S. Molecular insights into the therapeutic promise of targeting HMGB1 in depression. *Pharmacol Rep* 2021; **73**: 31-42 [PMID: 33015736 DOI: 10.1007/s43440-020-00163-6]

24 **D'Mello C**, Le T, Swain MG. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. *J Neurosci* 2009; **29**: 2089-2102 [PMID: 19228962 DOI: 10.1523/JNEUROSCI.3567-08.2009]

25 **Hennessy E**, Griffin ÉW, Cunningham C. Astrocytes Are Primed by Chronic Neurodegeneration to Produce Exaggerated Chemokine and Cell Infiltration Responses to Acute Stimulation with the Cytokines IL-1β and TNF-α. *J Neurosci* 2015; **35**: 8411-8422 [PMID: 26041910 DOI: 10.1523/JNEUROSCI.2745-14.2015]

26 **Maes M**, Leonard BE, Myint AM, Kubera M, Verkerk R. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2011; **35**: 702-721 [PMID: 21185346 DOI: 10.1016/j.pnpbp.2010.12.017]

27 **Steiner J**, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, Mawrin C, Brisch R, Bielau H, Meyer zu Schwabedissen L, Bogerts B, Myint AM. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? *J Neuroinflammation* 2011; **8**: 94 [PMID: 21831269 DOI: 10.1186/1742-2094-8-94]

28 **Bansal Y**, Singh R, Parhar I, Kuhad A, Soga T. Quinolinic Acid and Nuclear Factor Erythroid 2-Related Factor 2 in Depression: Role in Neuroprogression. *Front Pharmacol* 2019; **10**: 452 [PMID: 31164818 DOI: 10.3389/fphar.2019.00452]

29 **Hardingham GE**, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. *Nat Neurosci* 2002; **5**: 405-414 [PMID: 11953750 DOI: 10.1038/nn835]

30 **Chiba S**, Numakawa T, Ninomiya M, Richards MC, Wakabayashi C, Kunugi H. Chronic restraint stress causes anxiety- and depression-like behaviors, downregulates glucocorticoid receptor expression, and attenuates glutamate release induced by brain-derived neurotrophic factor in the prefrontal cortex. *Prog Neuropsychopharmacol Biol Psychiatry* 2012; **39**: 112-119 [PMID: 22664354 DOI: 10.1016/j.pnpbp.2012.05.018]

31 **Duman RS**, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. *Nat Med* 2016; **22**: 238-249 [PMID: 26937618 DOI: 10.1038/nm.4050]

32 **Malhi GS**, Mann JJ. Depression. *Lancet* 2018; **392**: 2299-2312 [PMID: 30396512 DOI: 10.1016/S0140-6736(18)31948-2]

33 **Eisenberger NI**, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. *Biol Psychiatry* 2010; **68**: 748-754 [PMID: 20719303 DOI: 10.1016/j.biopsych.2010.06.010]

34 **Capuron L**, Pagnoni G, Drake DF, Woolwine BJ, Spivey JR, Crowe RJ, Votaw JR, Goodman MM, Miller AH. Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. *Arch Gen Psychiatry* 2012; **69**: 1044-1053 [PMID: 23026954 DOI: 10.1001/archgenpsychiatry.2011.2094]

35 **Harrison NA**, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. *Biol Psychiatry* 2009; **66**: 407-414 [PMID: 19423079 DOI: 10.1016/j.biopsych.2009.03.015]

36 **Slavich GM**, Way BM, Eisenberger NI, Taylor SE. Neural sensitivity to social rejection is associated with inflammatory responses to social stress. *Proc Natl Acad Sci U S A* 2010; **107**: 14817-14822 [PMID: 20679216 DOI: 10.1073/pnas.1009164107]

37 **Felger JC**. Imaging the Role of Inflammation in Mood and Anxiety-related Disorders. *Curr Neuropharmacol* 2018; **16**: 533-558 [PMID: 29173175 DOI: 10.2174/1570159X15666171123201142]

38 **Muscatell KA**, Dedovic K, Slavich GM, Jarcho MR, Breen EC, Bower JE, Irwin MR, Eisenberger NI. Greater amygdala activity and dorsomedial prefrontal-amygdala coupling are associated with enhanced inflammatory responses to stress. *Brain Behav Immun* 2015; **43**: 46-53 [PMID: 25016200 DOI: 10.1016/j.bbi.2014.06.201]

39 **Mandelli L**, Petrelli C, Serretti A. The role of specific early trauma in adult depression: A meta-analysis of published literature. Childhood trauma and adult depression. *Eur Psychiatry* 2015; **30**: 665-680 [PMID: 26078093 DOI: 10.1016/j.eurpsy.2015.04.007]

40 **Baumeister D**, Akhtar R, Ciufolini S, Pariante CM, Mondelli V. Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-α. *Mol Psychiatry* 2016; **21**: 642-649 [PMID: 26033244 DOI: 10.1038/mp.2015.67]

41 **Köhler CA**, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, Stubbs B, Solmi M, Veronese N, Herrmann N, Raison CL, Miller BJ, Lanctôt KL, Carvalho AF. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. *Acta Psychiatr Scand* 2017; **135**: 373-387 [PMID: 28122130 DOI: 10.1111/acps.12698]

42 **Liu JJ**, Wei YB, Strawbridge R, Bao Y, Chang S, Shi L, Que J, Gadad BS, Trivedi MH, Kelsoe JR, Lu L. Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis. *Mol Psychiatry* 2020; **25**: 339-350 [PMID: 31427752 DOI: 10.1038/s41380-019-0474-5]

43 **Strawbridge R**, Hodsoll J, Powell TR, Hotopf M, Hatch SL, Breen G, Cleare AJ. Inflammatory profiles of severe treatment-resistant depression. *J Affect Disord* 2019; **246**: 42-51 [PMID: 30578945 DOI: 10.1016/j.jad.2018.12.037]

44 **Kappelmann N**, Lewis G, Dantzer R, Jones PB, Khandaker GM. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. *Mol Psychiatry* 2018; **23**: 335-343 [PMID: 27752078 DOI: 10.1038/mp.2016.167]

45 **Cao ZY**, Liu YZ, Li JM, Ruan YM, Yan WJ, Zhong SY, Zhang T, Liu LL, Wu R, Wang B, Wang W, Bi XY, Wang YX, Su WJ, Jiang CL. Glycyrrhizic acid as an adjunctive treatment for depression through anti-inflammation: A randomized placebo-controlled clinical trial. *J Affect Disord* 2020; **265**: 247-254 [PMID: 32090748 DOI: 10.1016/j.jad.2020.01.048]

46 **Wang B**, Huang X, Pan X, Zhang T, Hou C, Su WJ, Liu LL, Li JM, Wang YX. Minocycline prevents the depressive-like behavior through inhibiting the release of HMGB1 from microglia and neurons. *Brain Behav Immun* 2020; **88**: 132-143 [PMID: 32553784 DOI: 10.1016/j.bbi.2020.06.019]

47 **Nettis MA**, Lombardo G, Hastings C, Zajkowska Z, Mariani N, Nikkheslat N, Worrell C, Enache D, McLaughlin A, Kose M, Sforzini L, Bogdanova A, Cleare A, Young AH, Pariante CM, Mondelli V. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial. *Neuropsychopharmacology* 2021; **46**: 939-948 [PMID: 33504955 DOI: 10.1038/s41386-020-00948-6]

48 **Bauer IE**, Green C, Colpo GD, Teixeira AL, Selvaraj S, Durkin K, Zunta-Soares GB, Soares JC. A Double-Blind, Randomized, Placebo-Controlled Study of Aspirin and N-Acetylcysteine as Adjunctive Treatments for Bipolar Depression. *J Clin Psychiatry* 2018; **80** [PMID: 30549489 DOI: 10.4088/JCP.18m12200]

49 **Adzic M**, Brkic Z, Mitic M, Francija E, Jovicic MJ, Radulovic J, Maric NP. Therapeutic Strategies for Treatment of Inflammation-related Depression. *Curr Neuropharmacol* 2018; **16**: 176-209 [PMID: 28847294 DOI: 10.2174/1570159X15666170828163048]

50 **Brown C**, McKee C, Bakshi S, Walker K, Hakman E, Halassy S, Svinarich D, Dodds R, Govind CK, Chaudhry GR. Mesenchymal stem cells: Cell therapy and regeneration potential. *J Tissue Eng Regen Med* 2019; **13**: 1738-1755 [PMID: 31216380 DOI: 10.1002/term.2914]

51 **Mirzaei H**, Sahebkar A, Sichani LS, Moridikia A, Nazari S, Sadri Nahand J, Salehi H, Stenvang J, Masoudifar A, Mirzaei HR, Jaafari MR. Therapeutic application of multipotent stem cells. *J Cell Physiol* 2018; **233**: 2815-2823 [PMID: 28475219 DOI: 10.1002/jcp.25990]

52 **Abdelmawgoud H**, Saleh A. Anti-inflammatory and antioxidant effects of mesenchymal and hematopoietic stem cells in a rheumatoid arthritis rat model. *Adv Clin Exp Med* 2018; **27**: 873-880 [PMID: 29905411 DOI: 10.17219/acem/73720]

53 **Méndez-Ferrer S**, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, Scadden DT, Ma'ayan A, Enikolopov GN, Frenette PS. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. *Nature* 2010; **466**: 829-834 [PMID: 20703299 DOI: 10.1038/nature09262]

54 **Mezey E**. The therapeutic potential of bone marrow-derived stromal cells. *J Cell Biochem* 2011; **112**: 2683-2687 [PMID: 21678464 DOI: 10.1002/jcb.23216]

55 **Patrikoski M**, Sivula J, Huhtala H, Helminen M, Salo F, Mannerström B, Miettinen S. Different culture conditions modulate the immunological properties of adipose stem cells. *Stem Cells Transl Med* 2014; **3**: 1220-1230 [PMID: 25122689 DOI: 10.5966/sctm.2013-0201]

56 **Ra JC**, Shin IS, Kim SH, Kang SK, Kang BC, Lee HY, Kim YJ, Jo JY, Yoon EJ, Choi HJ, Kwon E. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. *Stem Cells Dev* 2011; **20**: 1297-1308 [PMID: 21303266 DOI: 10.1089/scd.2010.0466]

57 **Bowen JE**. Technical issues in harvesting and concentrating stem cells (bone marrow and adipose). *PM R* 2015; **7**: S8-S18 [PMID: 25864664 DOI: 10.1016/j.pmrj.2015.01.025]

58 **Lorenz E**, Uphoff D, Reid TR, Shelton E. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. *J Natl Cancer Inst* 1951; **12**: 197-201 [PMID: 14874130 DOI: 10.1093/jnci/12.1.197]

59 **Perry AR**, Linch DC. The history of bone-marrow transplantation. *Blood Rev* 1996; **10**: 215-219 [PMID: 9012918 DOI: 10.1016/S0268-960X(96)90004-1]

60 **Barnes DW**, Corp MJ, Loutit JF, Neal FE. Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. *Br Med J* 1956; **2**: 626-627 [PMID: 13356034 DOI: 10.1136/bmj.2.4993.626]

61 **Thomas ED**, Lochte HL Jr, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. *N Engl J Med* 1957; **257**: 491-496 [PMID: 13464965 DOI: 10.1056/nejm195709122571102]

62 **Lee M**, Jeong SY, Ha J, Kim M, Jin HJ, Kwon SJ, Chang JW, Choi SJ, Oh W, Yang YS, Kim JS, Jeon HB. Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo. *Biochem Biophys Res Commun* 2014; **446**: 983-989 [PMID: 24657442 DOI: 10.1016/j.bbrc.2014.03.051]

63 **Griffin MD**, Ryan AE, Alagesan S, Lohan P, Treacy O, Ritter T. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? *Immunol Cell Biol* 2013; **91**: 40-51 [PMID: 23207278 DOI: 10.1038/icb.2012.67]

64 **Sun L**, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. *Stem Cells* 2009; **27**: 1421-1432 [PMID: 19489103 DOI: 10.1002/stem.68]

65 **Freitag J**, Bates D, Wickham J, Shah K, Huguenin L, Tenen A, Paterson K, Boyd R. Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial. *Regen Med* 2019; **14**: 213-230 [PMID: 30762487 DOI: 10.2217/rme-2018-0161]

66 **Yu J**, Zheng C, Ren X, Li J, Liu M, Zhang L, Liang L, Du W, Han ZC. Intravenous administration of bone marrow mesenchymal stem cells benefits experimental autoimmune myasthenia gravis mice through an immunomodulatory action. *Scand J Immunol* 2010; **72**: 242-249 [PMID: 20696022 DOI: 10.1111/j.1365-3083.2010.02445.x]

67 **Németh K**, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, Hu X, Jelinek I, Star RA, Mezey E. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. *Nat Med* 2009; **15**: 42-49 [PMID: 19098906 DOI: 10.1038/nm.1905]

68 **Rojas M**, Xu J, Woods CR, Mora AL, Spears W, Roman J, Brigham KL. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. *Am J Respir Cell Mol Biol* 2005; **33**: 145-152 [PMID: 15891110 DOI: 10.1165/rcmb.2004-0330OC]

69 **Päth G**, Perakakis N, Mantzoros CS, Seufert J. Stem cells in the treatment of diabetes mellitus - Focus on mesenchymal stem cells. *Metabolism* 2019; **90**: 1-15 [PMID: 30342065 DOI: 10.1016/j.metabol.2018.10.005]

70 **Xing X**, Li Z, Yang X, Li M, Liu C, Pang Y, Zhang L, Li X, Liu G, Xiao Y. Adipose-derived mesenchymal stem cells-derived exosome-mediated microRNA-342-5p protects endothelial cells against atherosclerosis. *Aging (Albany NY)* 2020; **12**: 3880-3898 [PMID: 32096479 DOI: 10.18632/aging.102857]

71 **Luque-Campos N**, Contreras-López RA, Jose Paredes-Martínez M, Torres MJ, Bahraoui S, Wei M, Espinoza F, Djouad F, Elizondo-Vega RJ, Luz-Crawford P. Mesenchymal Stem Cells Improve Rheumatoid Arthritis Progression by Controlling Memory T Cell Response. *Front Immunol* 2019; **10**: 798 [PMID: 31040848 DOI: 10.3389/fimmu.2019.00798]

72 **Genc B**, Bozan HR, Genc S, Genc K. Stem Cell Therapy for Multiple Sclerosis. *Adv Exp Med Biol* 2019; **1084**: 145-174 [PMID: 30039439 DOI: 10.1007/5584\_2018\_247]

73 **Zappia E**, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. *Blood* 2005; **106**: 1755-1761 [PMID: 15905186 DOI: 10.1182/blood-2005-04-1496]

74 **Zhang L**, Dong ZF, Zhang JY. Immunomodulatory role of mesenchymal stem cells in Alzheimer's disease. *Life Sci* 2020; **246**: 117405 [PMID: 32035129 DOI: 10.1016/j.lfs.2020.117405]

75 **Vilaça-Faria H**, Salgado AJ, Teixeira FG. Mesenchymal Stem Cells-derived Exosomes: A New Possible Therapeutic Strategy for Parkinson's Disease? *Cells* 2019; **8** [PMID: 30717429 DOI: 10.3390/cells8020118]

76 **Costa-Ferro ZS**, Vitola AS, Pedroso MF, Cunha FB, Xavier LL, Machado DC, Soares MB, Ribeiro-dos-Santos R, DaCosta JC. Prevention of seizures and reorganization of hippocampal functions by transplantation of bone marrow cells in the acute phase of experimental epilepsy. *Seizure* 2010; **19**: 84-92 [PMID: 20080419 DOI: 10.1016/j.seizure.2009.12.003]

77 **Vezzani A**, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. *Nat Rev Neurol* 2011; **7**: 31-40 [PMID: 21135885 DOI: 10.1038/nrneurol.2010.178]

78 **Zanirati G**, Azevedo PN, Marinowic DR, Rodrigues F, de Oliveira Dias AC, Venturin GT, Greggio S, Simão F, DaCosta JC. Transplantation of bone marrow mononuclear cells modulates hippocampal expression of growth factors in chronically epileptic animals. *CNS Neurosci Ther* 2015; **21**: 463-471 [PMID: 25645708 DOI: 10.1111/cns.12382]

79 **Costa-Ferro ZS**, de Borba Cunha F, de Freitas Souza BS, Leal MM, da Silva AA, de Bellis Kühn TI, Forte A, Sekiya EJ, Soares MB, Dos Santos RR. Antiepileptic and neuroprotective effects of human umbilical cord blood mononuclear cells in a pilocarpine-induced epilepsy model. *Cytotechnology* 2014; **66**: 193-199 [PMID: 23929461 DOI: 10.1007/s10616-013-9557-3]

80 **Leal MM**, Costa-Ferro ZS, Souza BS, Azevedo CM, Carvalho TM, Kaneto CM, Carvalho RH, Dos Santos RR, Soares MB. Early transplantation of bone marrow mononuclear cells promotes neuroprotection and modulation of inflammation after status epilepticus in mice by paracrine mechanisms. *Neurochem Res* 2014; **39**: 259-268 [PMID: 24343530 DOI: 10.1007/s11064-013-1217-7]

81 **Walker LE**, Janigro D, Heinemann U, Riikonen R, Bernard C, Patel M. WONOEP appraisal: Molecular and cellular biomarkers for epilepsy. *Epilepsia* 2016; **57**: 1354-1362 [PMID: 27374986 DOI: 10.1111/epi.13460]

82 **Abi Chahine NH**, Wehbe TW, Hilal RA, Zoghbi VV, Melki AE, Habib EB. Treatment of Cerebral Palsy with Stem Cells: A Report of 17 Cases. *Int J Stem Cells* 2016; **9**: 90-95 [PMID: 27426090 DOI: 10.15283/ijsc.2016.9.1.90]

83 **Wehbe T**, Abi Saab M, Abi Chahine N, Margossian T. Mesenchymal stem cell therapy for refractory scleroderma: a report of 2 cases. *Stem Cell Investig* 2016; **3**: 48 [PMID: 27777937 DOI: 10.21037/sci.2016.09.03]

84 **Wei W**, Huang Y, Li D, Gou HF, Wang W. Improved therapeutic potential of MSCs by genetic modification. *Gene Ther* 2018; **25**: 538-547 [PMID: 30254305 DOI: 10.1038/s41434-018-0041-8]

85 **Rani S**, Ryan AE, Griffin MD, Ritter T. Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications. *Mol Ther* 2015; **23**: 812-823 [PMID: 25868399 DOI: 10.1038/mt.2015.44]

86 **Karlsen TA**, Aae TF, Brinchmann JE. Robust profiling of microRNAs and isomiRs in human plasma exosomes across 46 individuals. *Sci Rep* 2019; **9**: 19999 [PMID: 31882820 DOI: 10.1038/s41598-019-56593-7]

87 **Álvarez-Viejo M**. Mesenchymal stem cells from different sources and their derived exosomes: A pre-clinical perspective. *World J Stem Cells* 2020; **12**: 100-109 [PMID: 32184935 DOI: 10.4252/wjsc.v12.i2.100]

88 **Boulestreau J**, Maumus M, Rozier P, Jorgensen C, Noël D. Mesenchymal Stem Cell Derived Extracellular Vesicles in Aging. *Front Cell Dev Biol* 2020; **8**: 107 [PMID: 32154253 DOI: 10.3389/fcell.2020.00107]

89 **do Prado-Lima PAS**, Onsten GA, de Oliveira GN, Brito GC, Ghilardi IM, de Souza EV, Dos Santos PG, Salamoni SD, Machado DC, Duarte MMF, Barbisan F, da Cruz IBM, Costa-Ferro ZSM, daCosta JC. The antidepressant effect of bone marrow mononuclear cell transplantation in chronic stress. *J Psychopharmacol* 2019; **33**: 632-639 [PMID: 31018809 DOI: 10.1177/0269881119841562]

90 **Huang X**, Fei GQ, Liu WJ, Ding J, Wang Y, Wang H, Ji JL, Wang X. Adipose-derived mesenchymal stem cells protect against CMS-induced depression-like behaviors in mice via regulating the Nrf2/HO-1 and TLR4/NF-κB signaling pathways. *Acta Pharmacol Sin* 2020; **41**: 612-619 [PMID: 31796867 DOI: 10.1038/s41401-019-0317-6]

91 **Kin K**, Yasuhara T, Kameda M, Tomita Y, Umakoshi M, Kuwahara K, Kin I, Kidani N, Morimoto J, Okazaki M, Sasaki T, Tajiri N, Borlongan CV, Date I. Cell encapsulation enhances antidepressant effect of the mesenchymal stem cells and counteracts depressive-like behavior of treatment-resistant depressed rats. *Mol Psychiatry* 2020; **25**: 1202-1214 [PMID: 30108315 DOI: 10.1038/s41380-018-0208-0]

92 **Li J**, Wang H, Du C, Jin X, Geng Y, Han B, Ma Q, Li Q, Wang Q, Guo Y, Wang M, Yan B. hUC-MSCs ameliorated CUMS-induced depression by modulating complement C3 signaling-mediated microglial polarization during astrocyte-microglia crosstalk. *Brain Res Bull* 2020; **163**: 109-119 [PMID: 32681971 DOI: 10.1016/j.brainresbull.2020.07.004]

93 **Guo H**, Huang B, Wang Y, Zhang Y, Ma Q, Ren Y. Bone marrow mesenchymal stem cells-derived exosomes improve injury of hippocampal neurons in rats with depression by upregulating microRNA-26a expression. *Int Immunopharmacol* 2020; **82**: 106285 [PMID: 32088640 DOI: 10.1016/j.intimp.2020.106285]

94 **Li D**, Wang Y, Jin X, Hu D, Xia C, Xu H, Hu J. NK cell-derived exosomes carry miR-207 and alleviate depression-like symptoms in mice. *J Neuroinflammation* 2020; **17**: 126 [PMID: 32321532 DOI: 10.1186/s12974-020-01787-4]

95 **Belzung C**, Willner P, Philippot P. Depression: from psychopathology to pathophysiology. *Curr Opin Neurobiol* 2015; **30**: 24-30 [PMID: 25218233 DOI: 10.1016/j.conb.2014.08.013]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author's Membership in Professional Societies:** Associação Brasileira de Psiquiatria.

**Peer-review started:** February 28, 2021

**First decision:** April 20, 2021

**Article in press:**

**Specialty type:** Psychiatry

**Country/Territory of origin:** Brazil

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Byeon H, Sun C **S-Editor:** Wang JL **L-Editor: P-Editor:**

**Figure Legends**



**Figure 1 Synthesis of stress acute and chronic response on the inflammatory pathway.** (1-2) Stressors trigger a primary neuroendocrine response from the hypothalamic-pituitary-adrenal (HPA) axis. Hypothalamic Parvocellular neurons from the paraventricular nucleus secrete a corticotrophin-releasing hormone (CRH) and vasopressin. CRC induces, subsequently, the anterior hypophysis to release the adrenocorticotropic hormone, leading to a glucocorticoid secretion (cortisol in humans and corticosterone in rodents) by the adrenal cortex; (3) Acute physiological alterations prepare the human to fight or flight from stressors. These are evolutionary adaptive behaviors related to surveillance. Therefore, stress induces transient activation of HPA- axis activity paralleled by temporary increases in CRH transcription. Sympathetic-Adreno-Medullar axis is also activated in the stress response causing several physiological systemic changes. Acute stress also leads to an immunosuppressive state; (4) On the contrary, the exposure to chronic stress leads to excessive sustained elevated levels of stress hormones, including CRH and corticosterone, can be harmful and predispose to risk of several chronic non-transmissible diseases, including psychiatric disturbs; and (5) CaUnited Statesl mechanisms involving an increase in neural apoptosis an in the levels of some molecules associated to stress response, especially catecholamines. These processes induce the production of immunogenic Damage-associated molecular patterns (DAMPs) molecules. DAMPs can activate at least three inflammatory pathways that contribute to the increase of brain-blood barrier permeability, promoting ingress of some systemic peripheral inflammatory cells into the brain contributing to the neuroinflammatory states cause dysfunction and increase the risk of depression. HPA: Hypothalamic-pituitary-adrenal; PVN: Paraventricular nucleus; CRH: Corticotrophin-releasing hormone; VP: Vasopressin; ACTH: Adrenocorticotropic hormone; GC: Glucocorticoid; SAM: Sympathetic-Adreno-Medullar; DAMPs: Damage-associated molecular patterns; BBB: Brain-blood barrier.

**Table 1 Concise information of some studies on the effects of administration of mesenchymal stem cells with different sources and exosomes**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Type and characteristics of animal model used** | **Timing of intervention with cells after insult** | **Type of cells infused and route of administration** | **Major finding** |
| do Prado-Lima *et al*[89], 2019 | Wistar rats; depression, induced with CMS | 30th day of the CMS protocol | BMMCs from mice. Single-dose (1 × 107 cells). i.v. | Anti-inflammatory effects; Reduction of pro-inflammatory cytokines; increased expression of anti-inflammatory cytokines; BMMCs decreased 8'2-deoxyguanosine level |
| Huang *et al*[90], 2020 | C57BL/6 mice; depression-induced with CMS | 21th day of the CMS protocol | ADSCs from C57BL/6 mice; Repeated i.v. (3 times) 1 × 106 cells/dose  | ADSC treatment improved depressive-like behaviors. Reduced the expression of inflammatory factors in the serum Reduced microglial activation in the hippocampus |
| Kin*et al*[91], 2020 | Wistar Kyoto rats model of treatment-resistant depression | Day zero | MSCs from the bone marrow of Wistar rats. Single-dose 3 × 105 cells/5 µl i.v.  | MSCs encapsulation enhanced the treatment effects of MSCs in an animal model of treatment-resistant depression |
| Li *et al*[92], 2020 | Mice model depression induced by CUMS | 14th to the 42nd day CUMS protocol | MSC lines from human umbilical cords (hUC-MSCs)Repeated (4 times) 1 × 106/ dose i.v. | The hUC-MSCs treatment improved the anxiety-like behaviors of CUMShUC-MSCs, decreased pro-inflammatory factor levels, and increased anti-inflammatory factor levels. The hUC-MSCs inhibit microglial M1 polarization and the level of inflammation factors. The hUC-MSCs can alter the polarization of microglia by inhibiting C3a-C3aR signaling from reducing neuroinflammation. The hUC-MSCs decreased neuronal damage and synaptic deficits |
| Guo *et al*[93], 2020 | Sprague Dawley rats; Depression model by corticosterone injection | Day zero | BMSCs-derived exosomes 1 mL exosomes (100 μg/ 1 mL PBS) i.v. | The exosomes liBMSCs-derived improved hippocampal neuron injury of rats with depression by upregulating miR-26a |
| Li *et al*[94], 2020 | Male BALB/c mice depression, induced by CS | After 30 days of the CMS protocol | Exosomes from NK cells one time. Exosomes 66.42 μg i.v. | The exosomes miRNA-containing from NK cells could alleviate symptoms of chronic mild stress in mice. miRNA decreased the levels of pro-inflammatory cytokines (I L-1β, IL-6, and TNFα) released by astrocytes *in vivo*; Exosomes with low miR-207 levels showed decreased antidepressant activity *in vivo* experiments. Exosomes with low miR-207 levels showed decreased antidepressant activity MiR-207 could reduce the release of pro-inflammatory cytokines *in vitro* |

BMMC: Bone marrow mononuclear cells; ADSCs: Adipose-derived mesenchymal stem cells; CMS: Chronic mild stress; CS: Chronic stress; BDNF: Brain-derived neurotrophic factor; TrkB: Tyrosine receptor kinase B; BV2: Microglial cells; eMSC: Capsules with MSC; hUC-MSCs: Human umbilical cord mesenchymal stem cells; CUMS: Chronic unpredictable mild stress model; miR-26a: MicroRNA-26a; SOD: Superoxide dismutase; MDA: Malondialdehyde; LDH: Lactate dehydrogenase; TNFα: Tumor necrosis factor α; IL-1β: Interleukin-1β; NK: Natural killer cells; i.v.: Intravenously injected.

**Table 2 List of registered cell-based clinical trials for treating depression**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Study** | **Country** | **Target population** | **Product** | **Study design** | **Outcomes** |
| NCT02675556 | United States | Treatment-resistant depression (*n* = 80) | Allogeneic MSCs; 108 cells single i.v. infusion; source not reported | Phase I, placebo-controlled 1:1 | Incidence of any treatment-emergent serious adverse events; Reduction of Inflammation. |
| NCT03522545 | United States | Treatment-resistant bipolar depression (*n* = 30) | Allogeneic bone marrow-derived MSCs; dose not reported | Phase I, placebo-controlled | Change in depression as assessed by the MADRS Scale. |
| NCT03265808 | United States | Alcohol use disorder and major depression (*n* = 80) | Allogeneic MSCs; 108 cells single i.v. infusion; source not reported | Phase I/II | An incident of treatment emergent-serious adverse events |
| NCT04202770 | United States | Refractory depression; anxiety disorders; neurodegenerative diseases; (*n* = 300) | Focused ultrasound and exosomes  | Single group assignment | Beck depression inventory (BDI-II) |

MSCs: Mesenchymal stem cells.